Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec in Localized Prostate Cancer
EnerCom Opens Registration for the 31st Annual Energy Investment Conference August 17-19, 2026 in Denver, Colorado
QIMC Details Multiple Shallow Hydrogen-Bearing Zones in Drill Hole 26-02 and Advances Integrated Interpretation of Holes 1 and 2; Drill Hole 2 to be Extended to 700 Metres; Drill Mobilized for Hole 3
